2-Deoxy-D-glucose (2-DG): Metabolic Reprogramming in Cancer and Immunometabolism

Introduction: Beyond Glycolysis Inhibition—A New Frontier for 2-DG

2-Deoxy-D-glucose (2-DG) has long been recognized as a potent glycolysis inhibitor and metabolic pathway research tool, but recent advances reveal a more profound role in orchestrating cellular metabolic reprogramming. While previous studies and reviews have highlighted its utility in targeting tumor metabolism and viral replication, few have delved into its emerging significance in immunometabolism and the interplay with key signaling pathways such as PI3K/Akt/mTOR.¹ This article presents an in-depth exploration of 2-DG’s mechanisms, translational applications, and future potential—particularly emphasizing its capacity to modulate immune cell function and its synergy with modern therapeutic strategies.

Mechanism of Action of 2-Deoxy-D-glucose (2-DG): A Multifaceted Metabolic Oxidative Stress Inducer

2-DG is a glucose analog that enters cells via glucose transporters and is phosphorylated by hexokinase to 2-DG-6-phosphate. Unlike glucose, this metabolite cannot proceed through glycolysis, leading to the accumulation of intermediates and competitive inhibition of glycolytic enzymes. This disrupts ATP synthesis, imposes metabolic oxidative stress, and ultimately results in cytotoxicity—particularly in cells reliant on glycolysis for energy production.²

• ATP Synthesis Disruption: By interfering with glycolysis, 2-DG directly impairs ATP generation, inducing energetic stress and triggering cell death pathways in susceptible cancer and viral-infected cells.
• PI3K/Akt/mTOR Pathway Modulation: Glycolytic inhibition alters signaling through the PI3K/Akt/mTOR axis, a pathway intimately linked to cell growth, survival, and metabolic adaptation.
• Induction of Metabolic Oxidative Stress: The blockade of glycolytic flux leads to increased mitochondrial ROS, sensitizing cells to oxidative damage and promoting apoptosis or autophagy depending on context.

These mechanisms underpin 2-DG’s broad utility as a metabolic oxidative stress inducer, relevant for cancer research, viral replication inhibition, and immunometabolic studies.

2-DG in Cancer Metabolism: Targeting Glycolytic Addiction and Beyond

Glycolysis Inhibition in Cancer Research

Cancer cells, particularly those in hypoxic or nutrient-deprived microenvironments, often display a pronounced dependence on glycolysis for energy—termed the "Warburg effect." 2-DG exploits this metabolic vulnerability, with demonstrated efficacy against KIT-positive gastrointestinal stromal tumor (GIST) cell lines (IC50: 0.5 μM for GIST882, 2.5 μM for GIST430) and in non-small cell lung cancer models.² Notably, 2-DG enhances the action of chemotherapeutic agents like Adriamycin and Paclitaxel, resulting in slower tumor growth in xenograft models.

While prior reviews have focused on 2-DG’s precision targeting of tumor glycolysis, this article extends the discussion to the integration of glycolytic inhibition with immune modulation and metabolic reprogramming—areas of growing translational significance.

Disrupting Tumor Microenvironment via PI3K/Akt/mTOR Modulation

The PI3K/Akt/mTOR pathway is central to cancer metabolism and immune evasion. 2-DG’s ability to disrupt this signaling cascade not only impairs tumor cell proliferation but also modifies the metabolic landscape of the tumor microenvironment, reshaping immune cell infiltration and function. These effects position 2-DG as a bridge between metabolic and immunological cancer therapies.

Immunometabolic Reprogramming: Insights from Macrophage Polarization

A cutting-edge frontier in metabolic research is the modulation of immune cell function through metabolic reprogramming. The recent study by Chen et al. (2025) provides pivotal insights into how targeting metabolic pathways can reshape immune responses, specifically highlighting the role of the α7 nicotinic acetylcholine receptor (α7nAChR) in macrophage polarization.³

Although Chen et al. focused on Notopterol, their mechanistic findings are directly relevant to 2-DG research:

• M1/M2 Macrophage Polarization: Pro-inflammatory (M1) macrophages rely on glycolysis, while anti-inflammatory (M2) macrophages favor oxidative phosphorylation. Glycolysis inhibition by agents like 2-DG can shift macrophage polarization, suppressing chronic inflammation or enhancing anti-tumor immunity.
• Metabolic Reprogramming as a Therapeutic Strategy: By impairing glycolytic flux, 2-DG may foster an immunosuppressive or anti-inflammatory phenotype, paralleling the effects observed with Notopterol via α7nAChR activation.
• Translational Potential: These findings underscore the value of 2-DG not only as a cytotoxic agent but also as a modulator of immune cell metabolism, with applications spanning cancer immunotherapy and inflammatory disease.

This perspective builds on, but distinctly advances beyond, the scope of previous articles such as "2-Deoxy-D-glucose (2-DG): Advanced Insights in Glycolysis...", which examined bone metabolism and viral replication, by focusing on immune metabolic plasticity and the intersection of metabolic and inflammatory signaling.

2-DG in Antiviral Research: Suppressing Viral Replication and Protein Translation

Viruses often hijack host cell glycolysis to meet their biosynthetic and energetic needs. 2-DG's capacity to inhibit glycolytic flux extends to antiviral applications, as it has been shown to impair viral protein translation and replication—particularly during early infection stages.² For instance, 2-DG effectively inhibits porcine epidemic diarrhea virus (PEDV) replication and gene expression in Vero cells, demonstrating its broad-spectrum utility as a viral replication inhibition agent.

This mechanism is complementary to, yet distinct from, its action in cancer metabolism, providing researchers with a versatile tool for probing and manipulating metabolic dependencies in diverse biological systems.

Experimental Considerations for 2-DG: Practical Guidance and Best Practices

• Solubility: 2-DG is highly soluble at ≥105 mg/mL in water, with lower but adequate solubility in ethanol (≥2.37 mg/mL, warming and ultrasonic treatment required) and DMSO (≥8.2 mg/mL).
• Storage: Store at -20°C, and avoid long-term storage of solutions to preserve activity.
• Common Concentrations: Experimental protocols typically employ 5–10 mM treatment for 24 hours, but optimization may be required for specific cell types or applications.

For reproducible results, researchers are encouraged to use high-quality, validated products such as 2-Deoxy-D-glucose (2-DG) from APExBIO (SKU: B1027), which meets rigorous purity and solubility standards for biomedical research.

Comparative Analysis: 2-DG Versus Alternative Metabolic Inhibitors

While 2-DG remains the gold standard for glycolysis inhibition in cancer research, alternative agents—including 3-bromopyruvate, lonidamine, and selective mTOR inhibitors—offer unique advantages and limitations. Unlike targeted mTOR inhibitors, 2-DG offers system-wide metabolic stress by acting upstream of glycolytic branching points, impacting a broader range of metabolic and signaling pathways.

This comprehensive impact is particularly valuable in studies seeking to unravel the interplay between metabolism and immune cell function, as explored in immunometabolic reprogramming. For guidance on troubleshooting and optimizing experimental workflows, readers may consult this practical workflow guide, which complements our mechanistic focus by providing actionable experimental strategies.

Emerging Applications and Future Directions

Metabolic Pathway Research Tool in Immunometabolism

2-DG’s role as a metabolic pathway research tool is expanding, with growing interest in its capacity to reshape immune cell metabolism and function. Studies building on the foundational work by Chen et al. (2025) are poised to open new avenues for the treatment of inflammatory diseases, autoimmune disorders, and cancer immunotherapy—where metabolic plasticity governs therapeutic outcomes.

Furthermore, integration of 2-DG with agents targeting the PI3K/Akt/mTOR pathway or with immune checkpoint inhibitors may yield synergistic effects, offering a new paradigm for combination metabolic-immunological therapies.

Translational Impact

The translational potential of 2-DG is further underscored by its capacity to sensitize resistant tumors to chemotherapy and modulate antiviral responses. This article provides a broader context and deeper mechanistic analysis than resources such as protocol-centric guides, by exploring the foundational biology that will shape next-generation experimental design and clinical translation.

Conclusion and Future Outlook

2-Deoxy-D-glucose (2-DG) stands at the intersection of cancer metabolism, immunometabolic reprogramming, and antiviral research. Its ability to induce metabolic oxidative stress, disrupt ATP synthesis, and modulate the PI3K/Akt/mTOR signaling pathway positions it as a uniquely versatile tool for both fundamental and translational research. The integration of 2-DG into studies of immune cell metabolism—illuminated by recent advances in macrophage polarization and metabolic signaling (Chen et al., 2025)—opens the door to innovative therapies for cancer, inflammatory disease, and beyond.

For researchers seeking high-purity, reliable reagents for these advanced applications, APExBIO’s 2-Deoxy-D-glucose (2-DG) (SKU: B1027) provides the optimal starting point for high-impact metabolic pathway investigations.

---

References

1. See for example: 2-Deoxy-D-glucose (2-DG): Precision Targeting of Tumor an...
2. Product description and experimental data: 2-Deoxy-D-glucose (2-DG) by APExBIO
3. Chen, X. et al. Notopterol Attenuates Synovitis via α7nAChR-Dependent Metabolic Reprogramming of Macrophage Polarisation. Phytomedicine (2025). https://doi.org/10.1016/j.phymed.2025.157684